Daniel G. Baker
CIK: 0002046802
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Sep 10, 2026ARTV
Artiva Biotherapeutics, Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
16.3K shares- - Sep 8, 2026ARTV
Artiva Biotherapeutics, Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
13.8K shares- - May 29, 2026STTK
Shattuck Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
81K shares- - Apr 9, 2026CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
100K shares- - Sep 29, 2025CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
50K shares- - Aug 28, 2025STTK
Shattuck Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
66.3K shares- - Jun 24, 2025ARTV
Artiva Biotherapeutics, Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
13.8K shares- - Mar 21, 2025CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
100K shares- - Jan 28, 2025ARTV
Artiva Biotherapeutics, Inc.
Award(A)DirectDirector Stock Option (Right to Buy)
27.5K shares- - Nov 25, 2024CUE
Cue Biopharma, Inc.
Award(A)DirectStock Option (right to buy)
200K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 |  ARTV Artiva Biotherapeutics, Inc. | Award(A) Director Stock Option (Right to Buy) | 16,250 | - | - | Direct |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | Award(A) Director Stock Option (Right to Buy) | 13,750 | - | - | Direct |
| May 29, 2026 |  STTK Shattuck Labs, Inc. | Award(A) Stock Option (Right to Buy) | 81,000 | - | - | Direct |
| Apr 9, 2026 |  CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
| Sep 29, 2025 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Aug 28, 2025 | STTK Shattuck Labs, Inc. | Award(A) Stock Option (Right to Buy) | 66,300 | - | - | Direct |
| Jun 24, 2025 | ARTV Artiva Biotherapeutics, Inc. | Award(A) Director Stock Option (Right to Buy) | 13,750 | - | - | Direct |
| Mar 21, 2025 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 100,000 | - | - | Direct |
| Jan 28, 2025 | ARTV Artiva Biotherapeutics, Inc. | Award(A) Director Stock Option (Right to Buy) | 27,500 | - | - | Direct |
| Nov 25, 2024 | CUE Cue Biopharma, Inc. | Award(A) Stock Option (right to buy) | 200,000 | - | - | Direct |
1-10 of 10 transactions
About Baker Daniel G.
Baker Daniel G. (SEC CIK 0002046802) files insider reports with the SEC as Director of Artiva Biotherapeutics, Inc. (ARTV), Director of Shattuck Labs, Inc. (STTK) and CHIEF DEVELOPMENT OFFICER of Cue Biopharma, Inc. (CUE).
Signal8 holds 13 ownership filings by Baker Daniel G. (3 Form 3, 10 Form 4), filed between Nov 29, 2024 and Sep 14, 2026. Those filings report 10 transactions, from Nov 25, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Baker Daniel G.'s filings is in SAN DIEGO, CA.
Recent filings by Baker Daniel G.
- Sep 10, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
- Sep 8, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
- May 29, 2026: Grant or award of STTK derivative securities (Form 4, code A).
- Apr 9, 2026: Grant or award of CUE derivative securities (Form 4, code A).
- Sep 29, 2025: Grant or award of CUE derivative securities (Form 4, code A).
Other insiders filing for Artiva Biotherapeutics, Inc. (ARTV)
- Aslan Fred, Chief Executive Officer
- Horan Christopher, Chief Tech Operations Officer
- Bush Jennifer, COO, CLO, Compliance Officer
- Banerjee Subhashis, Chief Medical Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Stoppel Laura, Director